BRAVO: Background Regimen of Raltegravir on Virologic Outcome
Status:
Completed
Trial end date:
2009-06-15
Target enrollment:
Participant gender:
Summary
This is a retrospective chart review of participants in raltegravir expanded access program
and will compare virologic response in regimens not containing a protease inhibitor in the
antiretroviral background regimen to regimens containing a protease inhibitor in the
background regimen.
Details
Lead Sponsor:
Community Research Initiative of New England
Treatments:
HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium